Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The user is experiencing headaches and dizziness two weeks after starting finasteride at 1.25mg, concerned about potential brain fog affecting math studies. They mention hearing that headaches can be normal after starting finasteride.

A user is frustrated that their dermatologist requires blood and sperm tests before prescribing oral finasteride, despite already taking oral minoxidil. They prefer oral medication over topical treatments due to sensory issues and are considering asking their GP for a finasteride prescription or seeking alternatives online.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user is experiencing side effects from fluridil after switching from finasteride due to severe side effects. They are uncertain whether to continue with fluridil, considering it might be their body adjusting, a nocebo effect, or a permanent issue.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The user is frustrated with the lack of visible hair regrowth after 7-8 months of using finasteride and minoxidil, despite initial vellus hair growth. Others suggest patience, switching to oral minoxidil, or using additional treatments like dermastamping, microneedling, and red light therapy.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A 28-year-old started using finasteride and minoxidil for hair loss and is frustrated by insensitive comments from others about his balding, which is a sensitive topic for him. People, including a girl he's seeing, have made hurtful remarks, and the conversation includes discussions on societal double standards and advice to ignore such comments and focus on self-improvement.

The user experienced headaches and brain fog with a topical solution containing Dutasteride, Minoxidil, Tretinoin, Fluocinolone, Latanoprost, and Caffeine. They are considering switching to oral or topical Finasteride to see if it alleviates these side effects.

The user switched from topical minoxidil to oral minoxidil and added RU58841 to their hair loss treatment but hasn't seen improvement after several months, causing frustration. They also mentioned using finasteride and are confused about the lack of results despite oral minoxidil's reported high success rate.

A user who decided to shave their head after trying PRP for hair loss with minimal results, and the replies which commended them on how good they looked without it.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A user expressed distress over shaving their head due to hair loss before a job interview, feeling unattractive and depressed. Replies offered support, admiration for their bravery, and advice to embrace their new look with confidence.

The user has been using oral minoxidil, dutasteride, and RU58841 but continues to experience hair loss. They seek advice on why the treatments aren't working and if others have had similar experiences.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.